• Customer Care
  • (888) 123-4567

Pipeline

At Rise Therapeutics, we drive rapid and efficient drug development by integrating cutting-edge research, in-house GMP manufacturing, and deep clinical and regulatory expertise. Our streamlined approach enables us to translate innovative laboratory discoveries into first-in-class oral immunotherapies, accelerating their journey from concept to clinical validation. By leveraging our proprietary oral drug delivery platform and end-to-end development capabilities, we are advancing a robust pipeline of next-generation immunotherapies for the treatment of autoimmune diseases and cancer.

 

 

R-3750: Precision Therapy for Inflammatory Bowel Disease

R-3750 is a first-in-class oral immunotherapy designed to restore intestinal immune homeostasis and strengthen gut barrier integrity—two critical factors in treating inflammatory bowel disease (IBD). R-3750 engages dendritic cells lining the intestinal tract, increasing intestinal T regulatory cell populations, reducing chronic inflammation at its source.

Currently in a Phase 1 clinical trial for ulcerative colitis, R-3750 is being evaluated in a single and repeat dose study to assess the safety, drug exposure, and clinical activity. The study will enroll up to 36 participants, measuring disease severity improvements, key biomarkers, and pharmacodynamic responses.

🔹 Interested in participating? More details can be found at NCT05666960.

 

R-2487: A Next-Generation Approach for Rheumatoid Arthritis

R-2487 is a targeted oral immunotherapy designed to induce T regulatory cells and restore immune balance in autoimmune diseases, including rheumatoid arthritis (RA). Its unique mechanism of action activates specific immune pathways to reset regulatory deficiencies and reduce inflammatory cytokines that drive autoimmune pathology.

Currently enrolling RA patients in a Phase 1 clinical trial, R-2487 is undergoing a two-stage study to assess single and repeat dosing, evaluating safety, drug exposure, and clinical response. Up to 36 participants will be enrolled, with disease severity, biomarkers, and pharmacodynamic outcomes serving as key indicators of success.

🔹 Interested in participating? More details can be found at NCT05961592.

 

R-5280: Targeted Immune Modulation for Type 1 Diabetes

R-5280 is an oral immunotherapy designed to influence immune cell differentiation and cytokine production, addressing chronic inflammation in autoimmune diseases. Preclinical and clinical studies have demonstrated its potential to improve Type 1 Diabetes (T1D) outcomes by restoring immune balance and reducing beta-cell destruction.

Rise Therapeutics is conducting a double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy, and biomarker responses of R-5280 in newly diagnosed type 1 diabetes patients. The study will enroll 39 participants, assessing the effects of 12 weeks of oral therapy.

🔹 Interested in participating? More details can be found at NCT06057454.

 

R-5780: Revolutionizing Cancer Immunotherapy

R-5780 is an orally delivered immuno-oncology therapy designed to enhance immune checkpoint inhibitor activity and drive robust anti-tumor responses. R-5780 is a precision-engineered drug that selectively engages immune pathways critical to tumor control. By leveraging a deep understanding of novel immune system regulation mechanisms, R-5780 unlocks new potential for cancer immunotherapy by creating responsiveness in patients that are refractory to immune checkpoint inhibitor therapy or enhancing responsiveness in tumor indications that are classically non-responsive to immune checkpoint inhibitor therapy.

With its ability to potentiate immune checkpoint efficacy, R-5780 represents a next-generation approach to harnessing immune modulation for oncology—offering a novel, targeted, and patient-friendly strategy for fighting cancer.

🔹 Interested in participating? More details can be found at NCT06398418.